SC
PFE icon

Scotia Capital’s Pfizer PFE Stock Holding History

Scotia Capital’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-173,910
Closed -$5.81M – 817
2016
Q2 		$5.81M Buy
+173,910
New +$5.55M 0.12% 129
2016
Q1 		– Sell
-52,700
Closed -$1.61M – 817
2015
Q4 		$1.61M Hold
52,700
– – 0.04% 310
2015
Q3 		$1.57M Buy
+52,700
New +$1.69M 0.04% 304

Other funds holding PFE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Scotia Capital's PFE Position: Q2 2026 in Review

Scotia Capital reduced its Pfizer (PFE) stake by 24% in Q2 2026, selling an estimated $6.55M and leaving 808,429 shares worth $19.5M. The position accounts for 0.07% of the portfolio, ranked #152.

Scotia Capital first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $126M in Q4 2021. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Scotia Capital held 808,429 shares of Pfizer worth $19.5M as of Q2 2026.
  • Scotia Capital sold 250,397 Pfizer shares in Q2 2026, an estimated $6.55M.
  • Pfizer made up 0.07% of Scotia Capital's portfolio in Q2 2026, its #152 holding.
  • Scotia Capital first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Scotia Capital's Pfizer position peaked at $126M in Q4 2021.
  • 2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Scotia Capital's 13F filing for Q2 2026, filed 11 Aug 2026.